Combination of FOLFOXIRI Drugs with Oncolytic Coxsackie B3 Virus PD-H Synergistically Induces Oncolysis in the Refractory Colorectal Cancer Cell Line Colo320

Maxim Girod,Anja Geisler,Luisa Hinze,Leslie Elsner,Babette Dieringer,Antje Beling,Jens Kurreck,Henry Fechner

DOI: https://doi.org/10.3390/ijms25115618

IF: 5.6

2024-05-23

International Journal of Molecular Sciences

Abstract:FOLFOXIRI chemotherapy is a first-line therapy for advanced or metastatic colorectal cancer (CRC), yet its therapeutic efficacy remains limited. Immunostimulatory therapies like oncolytic viruses can complement chemotherapies by fostering the infiltration of the tumor by immune cells and enhancing drug cytotoxicity. In this study, we explored the effect of combining the FOLFOXIRI chemotherapeutic agents with the oncolytic coxsackievirus B3 (CVB3) PD-H in the CRC cell line Colo320. Additionally, we examined the impact of the drugs on the expression of microRNAs (miRs), which could be used to increase the safety of oncolytic CVB3 containing corresponding miR target sites (miR-TS). The measurement of cytotoxic activity using the Chou–Talalay combination index approach revealed that PD-H synergistically enhanced the cytotoxic activity of oxaliplatin (OX), 5-fluorouracil (5-FU) and SN-38. PD-H replication was not affected by OX and SN-38 but inhibited by high concentrations of 5-FU. MiR expression levels were not or only slightly elevated by the drugs or with drug/PD-H combinations on Colo320 cells. Moreover, the drug treatment did not increase the mutation rate of the miR-TS inserted into the PD-H genome. The results demonstrate that the combination of FOLFOXIRI drugs and PD-H may be a promising approach to enhance the therapeutic effect of FOLFOXIRI therapy in CRC.

biochemistry & molecular biology,chemistry, multidisciplinary

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to improve the sensitivity of the refractory colorectal cancer (CRC) cell line Colo320 to the chemotherapy drug FOLFOXIRI regimen. Although the FOLFOXIRI chemotherapy regimen is a first - line treatment for advanced or metastatic colorectal cancer, its efficacy is still limited. To overcome this limitation, researchers explored the effect of combining the FOLFOXIRI chemotherapy drug with oncolytic Coxsackievirus B3 (CVB3) PD - H. Specifically, researchers evaluated whether this combination therapy could synergistically induce tumor cell death by enhancing the cytotoxic effect of the drug, and examined the impact of this combination on the expression of specific microRNAs (miRs) to ensure the safety and effectiveness of oncolytic CVB3 containing the corresponding miR target sites (miR - TS).

The research results showed that PD - H could significantly enhance the cytotoxic effects of ofloxacin (OX), 5 - fluorouracil (5 - FU) and SN - 38 in the FOLFOXIRI drug, and the replication of PD - H was not affected by OX and SN - 38, but high - concentration 5 - FU had an inhibitory effect on it. In addition, drug treatment did not significantly increase the mutation rate of miR - TS inserted into the PD - H genome, indicating that this combination therapy has high safety while improving efficacy.

In conclusion, this study aims to improve the treatment effect of refractory colorectal cancer by combining the FOLFOXIRI drug with oncolytic CVB3 PD - H.